J Eur Acad Dermatol Venereol 2016 Feb 22;30(2):346-8. Epub 2014 Oct 22.
Institute of Dermatology, Policlinico A. Gemelli, Catholic University, Rome, Italy.
J Dermatol 2021 May 5. Epub 2021 May 5.
Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Nagoya, Japan.
A small proportion of individuals utilizing cosmetics containing rhododendrol developed leukoderma with various pathological conditions, in some cases indistinguishable from vitiligo. In this review, we investigate and evaluate the major considerations for developing rhododendrol-induced leukoderma based on data from original or review articles published in the literature to provide a wide range of information regarding the pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments. We compile and discuss the latest information, including data related to the cytotoxicity of rhododendrol, cytoprotective functions, and involvement of the immune system, and consider the possibility of novel treatments based on the differences between individual patients and on the mechanism underlying the onset of the condition. Read More
J Eur Acad Dermatol Venereol 2021 Apr 30. Epub 2021 Apr 30.
Université Côte d'Azur, CHU Nice, Department of Dermatology, Nice, France.
Background: Despite a solid rationale, the usefulness of antioxidants in treating vitiligo has not been clearly demonstrated. Combining superoxide dismutase (SOD) with a wheat gliadin biopolymer protects it during the passage through the gastrointestinal tract.Objective: To evaluate the efficacy of gliadin-protected SOD (GP-SOD), associated with narrowband ultraviolet B(NB-UVB), for treating vitiligo. Read More
Br J Dermatol 2021 Apr 8. Epub 2021 Apr 8.
Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris-Est University, UPEC, DHU VIC, EA7379, Créteil, France.
Background: Shared Decision-Making tools (SDMt) are visual tools developed to promote joint medical decision-making between physician and patient. In dermatology, there is a paucity of such tools.Objective: To develop and validate a SDMt in non-segmental vitiligo to be used in specialized consultation for vitiligo. Read More
Front Immunol 2021 5;12:613031. Epub 2021 Mar 5.
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
Vitiligo is an acquired depigmentation skin disease caused by immune-mediated death of melanocytes. The most common treatment for vitiligo is narrow band ultraviolet B phototherapy, which often is combined with topical therapies such as tacrolimus. However, patients' responses to these treatments show large variations. Read More
Pigment Cell Melanoma Res 2021 Mar 23. Epub 2021 Mar 23.
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
This is an exciting phase of vitiligo research with the current understanding of vitiligo pathogenesis and its translation to successful treatment. The pathogenetic origin of vitiligo revolves around autoimmunity with supporting role from many other factors like oxidative stress, inherent melanocyte defects, or defective keratinocytes and fibroblasts. Vitiligo can be classified into segmental or non-segmental depending upon the clinical presentation, or it can be classified as progressing or stable based on the activity of the disease. Read More